December 10th & 11th, 2026
15th edition
MARSEILLE, FR
Stand G3-F4

2023 Edition

Op2Lysis

Belgium

Op2Lysis is a French-Belgian biotech company developing innovative treatments for patients with cerebrovascular thrombotic diseases, including orphan drug indications. Looking to raise €5M EUR, to complete their €27M EUR Series A round. The proceeds will be to (i) complete a combined Phase 1/2 clinical study of their lead asset O2L-001 in patients with hemorrhagic stroke and (ii) develop pipeline, based on their unique NANOp2Lysis® platform, for other indications including ischemic stroke.

Scroll to Top

Before you leave…

Download the official BioFIT 2026 brochure

Discover the conference programme, partnership opportunities, attendee profiles, registration options and everything you need to make the most of BioFIT 2026.